Early administration of interleukin-6 inhibitors for patients with severe COVID-19 disease is associated with decreased intubation, reduced mortality, and increased discharge

OBJECTIVE: The aim of this observational study was to determine the optimal timing of interleukin-6 receptor inhibitor (IL6ri) administration for coronavirus disease 2019 (COVID-19). METHODS: Patients with COVID-19 were given an IL6ri (sarilumab or tocilizumab) based on iteratively reviewed guidelin...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Int J Infect Dis
Main Authors: Sinha, Pranay, Mostaghim, Anahita, Bielick, Catherine G., McLaughlin, Angela, Hamer, Davidson H., Wetzler, Lee M., Bhadelia, Nahid, Fagan, Maura A., Linas, Benjamin P., Assoumou, Sabrina A., Ieong, Michael H., Lin, Nina H., Cooper, Ellen R., Brade, Karrine D., White, Laura F., Barlam, Tamar F., Sagar, Manish
Formato: Artigo
Idioma:Inglês
Publicado em: The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7591937/
https://ncbi.nlm.nih.gov/pubmed/32721528
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ijid.2020.07.023
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados